Method for treatment of traumatic brain injury targeting aggregated peptides
A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain. An agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain is suitable for use in preventing, alleviating or treating traumatic brain injury. A method for predication of the risk of an individual for complications after a traumatic brain injury comprises detecting one or more aggregated forms of one or more peptides prone to aggregate as a result of a traumatic brain injury event, in the brain of the individual, wherein an increased level of such aggregates in the brain indicates an increased risk for complications.
1. A method of alleviating or treating traumatic brain injury in an individual, comprising administering to the individual a therapeutically effective and physiologically acceptable amount of an antibody which binds Aβ protofibrils, wherein said antibody is mAb158 or a humanized version thereof.
2. The method of claim 1 , wherein said traumatic brain injury is a result of an acute brain injury event.
3. The method of claim 1 , wherein said traumatic brain injury is a result of physical brain injury event.
4. The method of claim 1 , wherein said traumatic brain injury is a result of brain injury caused by stroke or hypoxia.
5. The method according to claim 1 , wherein said traumatic brain injury is mild traumatic brain injury.
6. The method according to claim 1 , wherein said traumatic brain injury is moderate traumatic brain injury.
7. The method according to claim 1 , wherein said traumatic brain injury is severe traumatic brain injury.
8. The method according to claim 1 , wherein said individual has been determined to be a carrier of an Apolipoprotein E4 allele as determined by genotyping.
9. The method according to claim 1 , wherein said individual has been determined to be of Apolipoprotein E3/E4 or Apolipoprotein E4/E4 genotype.
10. A method of binding an amount of Aβ protofibrils in the brain of an individual having a traumatic brain injury, comprising administering to the individual a physiologically acceptable amount of an antibody which binds Aβ protofibrils, wherein the antibody is mAb158 or a humanized version thereof, wherein the antibody is labelled with a detectable label, and measuring the localization and amount of the aggregated AP peptide binding with the labelled antibody.
11. Method according to claim 10 , wherein the antibody is fluorescent, magnetic, or radio labelled.